U.S. markets open in 8 hours 1 minute
  • S&P Futures

    4,121.50
    -3.00 (-0.07%)
     
  • Dow Futures

    32,724.00
    -13.00 (-0.04%)
     
  • Nasdaq Futures

    13,013.50
    -18.00 (-0.14%)
     
  • Russell 2000 Futures

    1,912.50
    -2.10 (-0.11%)
     
  • Crude Oil

    89.99
    -0.51 (-0.56%)
     
  • Gold

    1,792.40
    -1.60 (-0.09%)
     
  • Silver

    20.35
    -0.13 (-0.62%)
     
  • EUR/USD

    1.0217
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    2.7970
    0.0000 (0.00%)
     
  • Vix

    21.77
    +0.48 (+2.25%)
     
  • GBP/USD

    1.2080
    +0.0004 (+0.03%)
     
  • USD/JPY

    135.0000
    -0.1160 (-0.09%)
     
  • BTC-USD

    22,952.42
    -930.29 (-3.90%)
     
  • CMC Crypto 200

    532.95
    -24.40 (-4.38%)
     
  • FTSE 100

    7,488.15
    +5.78 (+0.08%)
     
  • Nikkei 225

    27,795.60
    -204.36 (-0.73%)
     

Sanofi caps out-of-pocket insulin cost at $35 for uninsured U.S. patients

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

June 29 (Reuters) - French drugmaker Sanofi said on Wednesday uninsured diabetes patients in the United States will pay no more than $35 for 30-day supply of insulin, in the wake of heightened public scrutiny over soaring prices of the life-saving drug.

Sanofi said the new price, down from the prior out-of-pocket cost of $99, will be effective from July 1.

U.S. lawmakers have pulled up healthcare companies over rising costs of insulin and the U.S. House of Representatives in March passed a bill capping monthly out-of-pocket insulin costs for those with health insurance at $35.

According to a 2020 Commonwealth Fund study, about two thirds of uninsured insulin users aged 18 to 64 paid the full price - an average of $900 a month - for the life-sustaining medicine.

Sanofi with Eli Lilly and Co and Novo Nordisk make up 90% of the U.S. market for insulin. In 2020, Lilly announced a new co-pay scheme that covers most of its insulin products, capping the out-of-pocket cost for insulin to $35 per month.

Around 37.3 million Americans, or 11.3% of the population, have diabetes, according to the American Diabetes Association.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)